PainReform Reaches 50% Enrollment in the Second Part of its Phase 3 Clinical Trial of PRF-110 in Bunionectomy

April 2, 2024

https://www.globenewswire.com/news-release/2024/04/02/2855954/0/en/PainReform-Reaches-50-Enrollment-in-the-Second-Part-of-its-Phase-3-Clinical-Trial-of-PRF-110-in-Bunionectomy.html

TEL AVIV, Israel, April 02, 2024 (GLOBE NEWSWIRE) — PainReform Ltd. (Nasdaq:PRFX) (“PainReform” or the “Company“), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced it has reached the 50% enrollment target for the second part of Phase 3 clinical trial of PRF-110 in bunionectomy. In total, over 200 patients have been enrolled, of up to approximately 400 patients at eight clinical sites across the U.S.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.